What Drives Survival in HER2+ Breast Cancer?
In a real-world study examining neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancer, researchers have identified key predictors of treatment response and long-term survival, providing critical insights for oncologists managing this aggressive disease.